Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Dintsios

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|November 16, 2016
[Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders]H Bender, C-M Dintsios
Health Economics Review|March 16, 2020
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyC M Dintsios, I Beinhauer
Journal of Clinical Epidemiology|June 21, 2015
When suddenly the evaluation became a validationC M Dintsios, C Niederstadt
Health Policy (Amsterdam, Netherlands)|December 13, 2025
The impact of the new 'guard rails' for price negotiations on pharmaceutical expenditure in Germany: A simulation exercise and retrospective analysisC Kranich, D Möller, C M Dintsios
Health Economics Review|December 19, 2019
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagreeC M Dintsios, F Worm, J Ruof, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|December 22, 2009
[Patient-reported and patient-weighted outcomes in ophthalmology]F Scheibler, R P Finger, R Grosselfinger, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|May 8, 2010
[IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario]A Schwalm, M Danner, A Seidl, et al.
BMJ Open Diabetes Research & Care|June 3, 2016
Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall studyC Bächle, H Claessen, S Andrich, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 11, 2021
Health care utilization and excess costs after pelvic fractures among older people in GermanyS Andrich, B Haastert, E Neuhaus, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|September 25, 2010
[Methods of health economic evaluation for health services research]A Icks, N Chernyak, K Bestehorn, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|November 16, 2016
[Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders]H Bender, C-M Dintsios
Health Economics Review|March 16, 2020
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyC M Dintsios, I Beinhauer
Journal of Clinical Epidemiology|June 21, 2015
When suddenly the evaluation became a validationC M Dintsios, C Niederstadt
Health Policy (Amsterdam, Netherlands)|December 13, 2025
The impact of the new 'guard rails' for price negotiations on pharmaceutical expenditure in Germany: A simulation exercise and retrospective analysisC Kranich, D Möller, C M Dintsios
Health Economics Review|December 19, 2019
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagreeC M Dintsios, F Worm, J Ruof, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft|December 22, 2009
[Patient-reported and patient-weighted outcomes in ophthalmology]F Scheibler, R P Finger, R Grosselfinger, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|May 8, 2010
[IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario]A Schwalm, M Danner, A Seidl, et al.
BMJ Open Diabetes Research & Care|June 3, 2016
Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall studyC Bächle, H Claessen, S Andrich, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 11, 2021
Health care utilization and excess costs after pelvic fractures among older people in GermanyS Andrich, B Haastert, E Neuhaus, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|September 25, 2010
[Methods of health economic evaluation for health services research]A Icks, N Chernyak, K Bestehorn, et al.
Pageof 1